NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kinvard Bio

Kinvard Bio

Private
Raleigh, North CarolinaHealthcare & Life Scienceshttps://www.kinvardbio.com/

Last Round

Grant

Jul 29, 2025

Total Funding Raised

$2.7M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Kinvard Bio is a drug discovery company developing antibiotics intended to combat multidrug-resistant bacterial infections. The company offers rational drug design and a proprietary synthetic chemistry platform to create a differentiated class of ribosome-targeting antibacterials, including oxepanoprolinamides, enabling clients to address the critical global health threat of antimicrobial resistance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

antimicrobial resistanceAMRsmall molecule antibioticsdrug-resistant infectionssuperbugsantibiotic developmentantibiotic resistanceoxepanoprolinamidesOPPsdrug discovery platformpreclinical biotechsynthetic chemistryribosome-targeting antibioticsgram-negative pathogens

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kinvard Bio Comparables

Compare Kinvard Bio with similar companies based on industry and business-model similarity.

Kinvard Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cūrza
81%
ArrePath
78%
VenatoRx Pharmaceuticals
75%

Kinvard Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 29, 2025
SeedFeb 24, 2025

Kinvard Bio Investors

Notable investors and investment history

Kinvard Bio investors
InvestorRounds
CARB-XGrant
Kineticos VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors grew 196% MoM.

  • Apr 23, 2026

    Monthly visitors increased 41% MoM.

Kinvard Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kinvard Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kinvard Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersRaleigh, North Carolina
Employee Range5
Year Founded2024
Last FundingJul 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.